{"name": "teneligliptin", "category": "drug", "content": "Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus.  It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or \"gliptins\".   == Creation == It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.   == Licensing and use ==   === Japan/Korea/India/Argentina === It is approved for use in Japan, Argentina, Korea and India.   == Pharmacology == Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme. Teneligliptin significantly controls glycemic parameters with safety.  No dose adjustment is required in renally impaired patients.   == References =="}